ClinicalTrials.gg
Not yet recruitingNCT07681674Updated Jul 2, 2026

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product

A Phase 2 interventional study of Zelenectide pevedotin and BT7480 in Advanced Solid Tumors, sponsored by BicycleTx Limited. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by BicycleTx Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Continued Access Protocol
  • Zelenectide pevedotin
  • Nuzefatide pevedotin
  • BT7480
  • Bicycle Drug Conjugate (BDC)
  • Bicycle TICA
  • Advanced Solid Tumors
03

In context

Lead sponsor

BicycleTx Limited is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be receiving a Bicycle product in another Bicycle-sponsored clinical study and will benefit from continued study treatment as assessed by the Investigator. The participant must be tolerating the treatment and the disease being treated has not grown on the treatment and have not met a treatment discontinuation criterion on the parent study.
  • Participants must be able to understand the study procedures and agree to participate in the study by providing written .
  • Pregnancy must be avoided while on treatment and for up to 6.5 months following end of study treatment.
  • Participants must have completed testing requirements of the Bicycle-sponsored parent study.

Exclusion criteria

Exclusion Criteria:

  • Participant is receiving pembrolizumab or nivolumab only, and has been treated for >24 months from start of therapy on the parent study.
  • Participant is receiving Bicycle product post-disease progression.
  • Participant has a new medical condition requiring treatment with strong cytochrome P450 3A () inhibitor or inducer while receiving zelenectide pevedotin or nuzefatide pevedotin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Zelenectide pevedotin

    Drug: Zelenectide pevedotin

  • Experimental
    BT7480

    Drug: BT7480

  • Experimental
    Nuzefatide pevedotin

    Drug: Nuzefatide pevedotin

Interventions

  • Participants will continue on the same treatment regimen they were receiving in their parent study.

  • DrugBT7480

    Participants will continue on the same treatment regimen they were receiving in their parent study.

  • Participants will continue on the same treatment regimen they were receiving in their parent study.

06

What researchers measure

Primary outcomes

  1. Monitor safety for participants receiving a Bicycle investigational product

    Incidence, severity, seriousness, relationship, and type of serious adverse events (SAEs), treatment-related adverse events (TRAEs), adverse events of clinical interest (AECIs), and treatment modifications as a result of any of these

    Time frame: Up to 48 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for May 2030, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
May 30, 2030
CompletionEst.
May 30, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681674
Lead sponsor
BicycleTx Limited
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
May 30, 2030 (estimated)
Completion
May 30, 2030 (estimated)
Last update
Jul 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zelenectide pevedotin · Nuzefatide pevedotin

Start the discussion